Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Key Highlights
- ➤Diranersen slowed CDR-SB clinical decline 38% at two years with 60 mg twice-yearly dosing
- ➤Two-year CDR-SB treatment difference reached 1.09 points, surpassing stated meaningful threshold
- ➤Clinical benefit increased across five of six measures versus 18-month results
- ➤Diranersen was generally well tolerated through two years, with no new safety signals
- ➤Biogen plans continued diranersen development in a Phase 3 trial
Expert Statements
Priya Singhal, Executive Vice President and Head of Development at Biogen
“The two-year data presented at CTAD mark an important milestone for diranersen, demonstrating not only sustained clinical benefit but also an increasing magnitude of effect at two years”
Priya Singhal, Executive Vice President and Head of Development at Biogen
“These findings strengthen the growing body of evidence supporting tau as a therapeutic target and underscore the potential of diranersen to meaningfully impact disease progression for people living with early Alzheimer’s disease.”
Lawren VandeVrede, Principal investigator in the Phase 2 CELIA study at the University of California, San Francisco
“These are highly encouraging results, particularly given the progressive nature of Alzheimer’s disease”
Lawren VandeVrede, Principal investigator in the Phase 2 CELIA study at the University of California, San Francisco
“The increasing separation observed between 18 months and two years is remarkable and clinically meaningful. For patients and families, slowing clinical decline means more time in early stages, preserving independence, and remaining connected to the people and experiences that matter most.”
* Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment difference * Greater slowing of clinical decline across 5 of 6 measures at two years compared with 18 months (Week 76) in the 60 mg dose group * Clinical benefits were observed across all doses studied, with the 60 mg dose group showing compelling efficacy and a favorable benefit-risk profile * Data presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference CAMBRIDGE, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures of cognition, function and disease progression, with the 60 mg twice-yearly regimen showing the largest treatment effects at two years.
Get started
Create a free account to read the full story.
